Which therapy may be considered for ITP in refractory cases?

Which therapy may be considered for ITP in refractory cases?

• A. Splenectomy
• B. Platelet transfusion as first-line treatment
• C. Vitamin K administration
• D. Desmopressin

Answer: (A)

In refractory ITP, removing the spleen can yield durable remissions because the spleen is a primary site where autoantibody-coated platelets are sequestered and destroyed. By performing splenectomy, you reduce platelet clearance and often extend platelet lifespan, which can lead to sustained increases in platelet count even after other therapies have failed. This approach is considered after first-line treatments (like steroids ± IVIG) have not produced lasting responses, particularly in adults. Platelet transfusion isn’t a long‑term solution in ITP because the circulating autoantibodies rapidly target and destroy transfused platelets, making any rise in counts temporary. Vitamin K administration doesn’t address immune-mediated platelet destruction and is used for coagulation factor deficiencies, not ITP. Desmopressin can transiently improve bleeding in certain bleeding disorders but doesn’t treat the underlying immune destruction of platelets in ITP. Splenectomy targets the underlying mechanism and, when feasible, offers a chance for lasting improvement.

In refractory ITP, removing the spleen can yield durable remissions because the spleen is a primary site where autoantibody-coated platelets are sequestered and destroyed. By performing splenectomy, you reduce platelet clearance and often extend platelet lifespan, which can lead to sustained increases in platelet count even after other therapies have failed. This approach is considered after first-line treatments (like steroids ± IVIG) have not produced lasting responses, particularly in adults.

Platelet transfusion isn’t a long‑term solution in ITP because the circulating autoantibodies rapidly target and destroy transfused platelets, making any rise in counts temporary. Vitamin K administration doesn’t address immune-mediated platelet destruction and is used for coagulation factor deficiencies, not ITP. Desmopressin can transiently improve bleeding in certain bleeding disorders but doesn’t treat the underlying immune destruction of platelets in ITP. Splenectomy targets the underlying mechanism and, when feasible, offers a chance for lasting improvement.